NCCN Awarded $2 Million in Research Funding from Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies
The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Infinity Pharmaceuticals, Inc. to facilitate studies of duvelisib in the treatment of hematologic malignancies.
9-Feb-2016 9:00 AM EST Add to Favorites
Groundbreaking Collaborative Breast Cancer Study Aims to Unlock the Doors of Individualized Patient Care with Big Data
Thirty-two researchers from 14 institutions joined forces to identify personalized treatment options for a patient with metastatic triple-negative breast cancer.
27-Jan-2016 9:30 AM EST Add to Favorites
The new NCCN Guidelines for Vulvar Cancer are the most comprehensive and up-to-date clinical guidelines available to clinicians today.
26-Jan-2016 1:30 PM EST Add to Favorites
NCCN Awards Research Grants to Five Investigators to Study Effectiveness of Enzalutamide in Various Cancers
The NCCN Oncology Research Program has awarded five research grants to investigate the effectiveness of enzalutamide in mantle cell lymphoma and endometrial, hepatocellular, and prostate cancers.
13-Jan-2016 9:00 AM EST Add to Favorites
The NCCN Oncology Research Program has awarded three research grants to investigate the safety and effectiveness of volasertib in hematologic malignancies.
11-Jan-2016 8:00 AM EST Add to Favorites
NCCN Awarded $2 Million in Research Funding From Peregrine Pharmaceuticals to Study Bavituximab in Various Cancers
The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Peregrine Pharmaceuticals, Inc. to facilitate studies of bavituximab in various cancers.
6-Jan-2016 8:00 AM EST Add to Favorites
NCCN Collaborates with Bristol-Myers Squibb to Study PD-L1 Expression and Test Interpretation in Lung Cancer
NCCN is collaborating with Bristol-Myers Squibb to promote the advancement of scientific knowledge concerning programmed death-ligand 1 (PD-L1) protein expression and other immune markers in lung cancer.
30-Nov-2015 10:30 AM EST Add to Favorites
The NCCN Foundation welcomes Heather Kopecky, PhD, MBA; Marc Samuels, JD, MPH; and Susan Stein, MPH, as the newest representatives to its Board of Directors.
20-Nov-2015 3:00 PM EST Add to Favorites